<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; registry</title>
	<atom:link href="http://www.tapanray.in/tag/registry/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>The Curious Conundrum of New Drugs Approval Process</title>
		<link>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-curious-conundrum-of-new-drugs-approval-process</link>
		<comments>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/#comments</comments>
		<pubDate>Mon, 18 Jan 2016 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alatrofloxacin]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Aprotinin]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Cochrane]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[curious]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[Drotrecogin alfa]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Economist]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[full]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[International]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[Lumiracoxib]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Matthew Herder]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Propoxyphene]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[registry]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Rofecoxib]]></category>
		<category><![CDATA[Rosiglitazone]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Sibutramine]]></category>
		<category><![CDATA[Tamiflu]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tegaserod]]></category>
		<category><![CDATA[Tetrazepam]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Vioxx]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7360</guid>
		<description><![CDATA[Fathoming the details of just a short span of time, not going beyond the last 10 years, I find from the published data that many new drugs, such as, Alatrofloxacin, Aprotinin, Drotrecogin alfa, Lumiracoxib, Propoxyphene, Rofecoxib, Rosiglitazone, Sibutramine, Tegaserod, Tetrazepam, were &#8230; <a href="http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Havoc’ and its ‘Aftermath’: Clinical Trials in India</title>
		<link>http://www.tapanray.in/havoc-and-its-aftermath-clinical-trials-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=havoc-and-its-aftermath-clinical-trials-in-india</link>
		<comments>http://www.tapanray.in/havoc-and-its-aftermath-clinical-trials-in-india/#comments</comments>
		<pubDate>Mon, 14 Jan 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[aftermath]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[death]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[havoc]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[Parialmentary]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[registry]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[volunteer]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1427</guid>
		<description><![CDATA[Just as the New Year dawned, on January 3, 2013, in an embarrassing indictment to the Government, the bench of honorable justices R.M Lodha and A.R Dave of the Supreme Court reportedly observed that uncontrolled Clinical Trials (CT) are creating &#8230; <a href="http://www.tapanray.in/havoc-and-its-aftermath-clinical-trials-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/havoc-and-its-aftermath-clinical-trials-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
